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Abstract
Wear particle-induced peri-implant loosening (Aseptic prosthetic loosening) is one of the most common causes of total joint
arthroplasty. It is well established that extensive bone destruction (osteolysis) by osteoclasts is responsible for wear particle-
induced peri-implant loosening. Thus, inhibition of osteoclastic bone resorption should prevent wear particle induced
osteolysis and may serve as a potential therapeutic avenue for prosthetic loosening. Here, we demonstrate for the first time
that saliphenylhalamide, a new V-ATPase inhibitor attenuates wear particle-induced osteolysis in a mouse calvarial model. In
vitro biochemical and morphological assays revealed that the inhibition of osteolysis is partially attributed to a disruption in
osteoclast acidification and polarization, both a prerequisite for osteoclast bone resorption. Interestingly, the V-ATPase
inhibitor also impaired osteoclast differentiation via the inhibition of RANKL-induced NF-kB and ERK signaling pathways. In
conclusion, we showed that saliphenylhalamide affected multiple physiological processes including osteoclast
differentiation, acidification and polarization, leading to inhibition of osteoclast bone resorption in vitro and wear
particle-induced osteolysis in vivo. The results of the study provide proof that the new generation V-ATPase inhibitors, such
as saliphenylhalamide, are potential anti-resorptive agents for treatment of peri-implant osteolysis.
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Introduction
Total joint arthroplasty (TJA) is the gold standard for the
treatment of end-stage joint diseases such as osteoarthritis and
rheumatoid arthritis [1]. Globally, approximately 1.5 million cases
of total arthroplasty are carried out per annum [2]. Although
extensive efforts have been made to improve the efficacy and
quality of TJA, there are still numerous caveats that limit the long-
term success of arthroplasty surgery. Aseptic prosthetic loosening is
one of the most common causes of TJA. It occurs secondary to a
cascade of chronic inflammatory events stimulated and main-
tained by wear particles [3,4,5,6]. The underlying mechanisms of
particle-induced osteolysis are complex, involving numerous
cytokines, chemokines, growth factors, and cell types. Wear
particles stimulate macrophages, fibroblasts, foreign body giant
cells, and T lymphocytes to release vast arrays of proinflammatory
cytokines and chemokines including tumour necrosis factor-a
(TNFa), interleukins-1, 6, 11 and 17 (IL-1, -6, -11, -17),
prostaglandin E2 (PGE2) and macrophage-colony stimulating
factor (M-CSF) all of which induce receptor activator of nuclear
factor-k B ligand (RANKL) expression by osteoblasts, marrow
stromal cells and activated T-cells [4,7,8,9,10,11,12,13,14,15,16].
Increased RANKL levels at the implant site exacerbates the
differentiation and activation of the already abundant pool of
monocyte/macrophage precursors surrounding the prosthetic
implant into mature osteoclasts thus shifting the local homeostasis
to activated bone destruction [17,18,19,20,21].
Given that the central mechanism of wear particle-induced
osteolysis is increased osteoclastic bone resorption, therapeutic
targeting of osteoclast function presents a logical avenue towards
treating or alleviating aseptic loosening after total joint replace-
ment. V-ATPases are distinguished enzyme complexes that
differentiate osteoclasts from macrophages and other cells. These
proton pumps play vital roles in osteoclastic bone resorption by
mediating extracellular acidification of the resorption pit between
the osteoclast ruffled border plasma membrane and the bone
surface [22,23,24]. The critical importance of V-ATPases is
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and mice of specific V-ATPase subunits (e.g. a3) exhibiting
osteopetrotic phenotypes owing to impaired osteoclastic function
[25,26,27,28,29,30,31,32]. To this end, we speculated that agents
targeting V-ATPase could represent a potentially new class of anti-
resorptive therapeutics for the treatment of particle-induced
osteolysis after total joint replacement.
Although several V-ATPase inhibitors, such as the plecoma-
crolide antibiotics bafilomycin and concanamycin, have been
shown to be effective in inhibiting osteoclast function [33], the
ionophoric properties and the lack of specificity on V-ATPase
cause systemic unacceptable toxicity when administered to
animals. Currently these V-ATPase inhibitors have been preclud-
ed from the pharmacological use in vivo [34]. Salicylihalamide A
(saliA), a marine metabolite represents a new generation of novel
V-ATPase inhibitors that exhibit its specific inhibition profile and
unique selectivity towards mammalian V-ATPases [34]. SaliA acts
on the V0 domain of the V-ATPase complex via a mode of action
that is distinct from the other two macrolides, bafilomycin and
concanamycin [35]. Here, we have shown for the first time that
saliphenylhalamide (1) effectively attenuates titanium particle-
induced osteolysis in mouse calvaria in vivo; (2) potently inhibits
osteoclast acidification function and polarization in vitro; and (3)
impairs osteoclast formation via disruption of NF-kB and ERK
signalings, an unexpected feature that has yet to be assigned to V-
ATPase inhibitors.
Results
SaliPhe is a potent inhibitor of the osteoclastic V-ATPase
acidification machinery
Bone resorption by osteoclasts is strictly dependent on the V-
ATPase-mediated acidification machinery. Thus, selective inhib-
itors of the V-ATPase complex hold great promise for targeted
anti-resorptive therapy. As an initial step towards investigating the
therapeutic potential of saliPhe as a new anti-resorptive agent we
first compared its ability of blocking intracellular acidification in
osteoclasts with bafilomycin, an established inhibitor of the
osteoclastic V-ATPase complex. For this purpose, acridine orange
(AO) fluorescence quenching assays were performed on mature
osteoclasts derived from mouse bone marrow macrophages
(BMM) stimulated with M-CSF and RANKL (5-days) and then
exposed to either the presence or absence of saliPhe or bafilomycin
at varying concentrations. AO quenching has been routinely
employed to monitor the intracellular acidification status of a
variety of cells and organelles [25]. Upon entering acidified
compartments, unprotonated AO (green light; Em535 nm)
becomes protonated and emits orange/red light (Em580 nm)
when excited by blue light (Ex492 nm). Fluorescence shift from
green to orange/red indicates normal intracellular acidification.
As shown in Figure 1A, cells treated with saliPhe (10 nM,
20 nM, 40 nM, and 80 nM) or bafilomycin (0.625 nM, 1.25 nM)
dose-dependently inhibited AO quenching as evidenced by the
predominantly green fluorescence signal of the Ex492/Em535
fluorescence spectra, and little shift towards the orange/red
fluorescence observed, reflecting reduced acidity in the treated
osteoclasts. In contrast, osteoclasts treated with vehicle alone
displayed typical intracellular acidification spectra as demonstrat-
ed by the fluorescence shift of AO fluorescence from green to
orange/red (orange/yellow spectra when merged) (Fig. 1A,
control). Additionally, the inhibitory effect on acidification can
be observed as early as 5 and 10 mins following treatment of cells
with either saliPhe or bafilomycin (Fig. 1C). Quantification of AO
fluorescence intensity at Ex492/Em535 using a spectrophotometer
further confirmed the dose-dependent elevation of intracellular pH
levels (decrease acidity) by saliPhe and bafilomycin (Fig. 1B;
*P,0.05, **P,0.01). Taken together, these data indicate a clear
impairment in intracellular acidification in osteoclasts following
saliPhe treatment, suggesting that saliPhe may be a potent
inhibitor of the osteoclastic acidification machinery.
V-ATPase inhibitors prevented wear particles-induced
osteolysis in vivo
Having established that saliPhe is indeed a specific inhibitor of
V-ATPase-mediated acidification in osteoclasts we next explored
its potential protective effects under pathological settings of
osteolysis. To this end, we utilized a titanium particle-induced
mouse calvarial osteolysis model to directly compare the effects of
saliPhe and bafilomycin on localized particle-induced osteolysis.
To achieve this, thirty micrograms of titanium wear particle was
embedded under the periosteum at the middle suture of the
calvaria in 8-week-old C57BL/J6 mice treated without or with
saliPhe (250 nM and 500 nM) or bafilomycin (100 nM and
250 nM). Importantly, no fatalities occurred during or after
particle implantation and mice retained normal activity through-
out the duration of the experiment. In vivo toxicity of bafilomycin
and saliPhe has been previously reported [36]. After 14-days, the
mice were sacrificed and the degree of particle-induced osteolysis
was assessed using high-resolution mCT and histology. As
expected, implantation of titanium wear particles induced severe
osteolysis as evidenced by the extensive eroded surface observed
on the calvaria (vehicle; PBS injection) when compared to negative
control (sham; no titanium particles) (Figure 2A). In contrast,
treatment of either saliPhe and/or bafilomycin led to a significant
reduction in the extent of wear particle-induced bone destruction,
particularly at higher doses (500 nM of saliPhe and 250 nM of
bafilomycin) (Fig. 2A). Quantitative analysis of bone parameters
further confirmed the wear particle–induced osteolysis with a
significantly reduction in BV/TV (Fig. 2B; *P,0.05, **P,0.01)
and significant increase in total bone porosity of the calvaria
(Fig. 2C; **p,0.01).
Histological H&E assessment and histomorphometric analysis
further confirmed the attenuation of wear particle-induced bone
erosion by both saliPhe and bafilomycin (Fig. 3A). In this instance,
wear particle injection induced an inflammatory infiltration of
lymphocyte and macrophages into the site of injection, as well as
multiple osteoclasts lining the eroded bone surface as revealed by
staining for the osteoclast marker enzyme tartrate-acid resistant
phosphatase (TRAP) (Fig. 3A; white arrowheads). Consistent with
the mCT quantitation, histomorphometric analysis demonstrated
that both low and high dose of saliPhe and bafilomycin
significantly reduced the extent of bone erosion induced by the
titanium particles (*P,0.05, **P,0.01) additionally with a trend
of decrease in osteoclast numbers (Fig. 3B, C, D). Collectively,
these data imply that osteoclast resorption function, rather than
osteoclast formation rates, were primarily disrupted by both V-
ATPase inhibitors in vivo (Fig. 3A and D), attesting to the notion
that V-ATPase inhibitors like saliPhe serves as effective anti-
resorptive agents for the treatment and/or inhibition of particle-
induced osteolysis.
SaliPhe and bafilomycin impaired osteoclast bone
resorption in vitro
Next, we assessed the direct effect of saliPhe and bafilomycin on
osteoclast bone-resorptive function in vitro using osteoclasts derived
from mouse BMMs. BMM-derived pre-osteoclasts stimulated with
M-CSF and RANKL for 3 days were cultured on devitalized
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concentrations of the respective V-ATPase inhibitors and then
examined for resorption pit formation capacity 48-hrs post-
culture. As revealed by scanning electron microscopy (SEM), at
doses from 10 nM, saliPhe effectively inhibited osteoclast-mediat-
ed bone resorption (,50%) with almost completely blockade of
bone resorption attained at higher concentrations (80 nM) (Fig. 4A
and B; **P,0.01). Comparatively, bafilomycin exhibited higher
potency for bone resorption inhibition i.e. ,65% inhibition at
0.625 nM and almost complete abolishment of bone resorption at
1.25 nM (Fig. 4A and B; **P,0.01).
Since the formation of a well-polarized F-actin ring/sealing
zone is an essential prerequisite for efficient bone resorption by
osteoclasts we also explored the effect of saliPhe and bafilomycin of
F-actin ring formation. As expected, characteristic podosomal
condensation and F-actin ring formation was observed in
untreated control (Ctrl) osteoclasts as visualized by Phalloidin-
Alexa Fluor 647 staining and confocal microscopy (Figure 4C). On
the other hand, treatment with either saliPhe or bafilomycin
resulted in drastic alterations in F-actin ring formation and
morphology. In this instance, F-actin tended to aggregate as small
pleiomorphic rings that appeared largely unstructured and often
varied in both size and number after either saliPhe or bafilomycin
treatment (Fig. 4C). Given the fact that SaliPhe and Bafilomycin
bind to the V0 domain [37,38] while direct interaction between V-
ATPase and F-actin ring only occurs in B2 and C1 of V1 domain
[25,39], thus we speculated that these two inhibitors may
indirectly disrupt F-actin ring formation via the V1 domain. In
support of this, bioluminescence resonance energy transfer
(BRET) assay showed that the disruption of F-actin ring is at
least not due to the alterations in V0 subunits by saliPhe or
bafilomycin treatment (Figure S1A). It is noteworthy that B2 and
C1 expression level is also not altered by saliPhe or Bafilomycin
treatment (Figure S1B and S1C). Taken together, while SaliPhe
and bafilomycin exert clear effects on F-actin ring formation, these
changes appear to be independent, at least in part, from the V-
ATPase V1/V0 expression and assembly. Further studies will be
required to define the exact mechanism underlying these
cytosketelal aberrations.
Figure 1. SaliPhe and bafilomycin potently attenuate intracellular acidification in osteoclasts in vitro. (A) Fluorescence quenching of
acridine orange (AO) in BMM-derived osteoclasts following saliPhe or bafilomycin treatment. Mouse BMM-derived osteoclasts were pre-treated for
24 hrs with various concentrations of saliPhe or bafilomycin prior to incubation with 5 mg/ml AO for 30 mins at 37uC. Fluorescence quenching was
measured with excitation 492 nm and emission 535 nm. Fluorescence shift of acridine orange from green to orange/red indicate normal intracellular
acidification. Overlay (orange/yellow) of red and green fluorescence spectra are presented. (B) Acridine orange readings of the green wavelength
(Ex492 nm and Em535 nm) was measured in live osteoclasts using the FLUOStar Optima spectrophotometer (BMG LabTech) showing the effect of
saliPhe and bafilomycin. The results are representative of three independent experiments performed in triplicates (mean 6 SEM). (C) Acridine orange
quenching assay in osteoclasts. The mature osteoclasts were incubated with 5 mg/ml AO for 30 mins followed by adding V-ATPase inhibitors for
observing acridine orange quenching at 0, 5 and 10 min under fluorescent microscope. The asterisks indicate significant differences between the
inhibitors and control (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0034132.g001
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V-ATPase-driven acidification and specific V-ATPase subunits
have been recently implicated in the modulation osteoclastogenesis
[29,40]. Therefore, we further explored whether blockade of V-
ATPase-mediated acidification by saliPhe and bafilomycin might
also affect RANKL-induced osteoclast formation. To test this,
murine M-CSF-dependent BMMs were treated with 100 ng/ml
RANKL for 5 days to form osteoclasts in the absence or presence
of varying concentrations of saliPhe (10 nM, 20 nM, 40 nM and
80 nM) or bafilomycin (0.625 nM and 1.25 nM). As shown in
figure 5, both saliPhe and bafilomycin significantly reduced the
number of TRAP-positive multinucleated osteoclast (.3 nuclei),
up to 25% and 40%, respectively at maximal dosages i.e. 80 nM
saliPhe and 1.25 nM bafilomycin (Fig. 5A and B; *P,0.05,
**P,0.01). Interestingly, the size of the osteoclasts formed in the
presence of both V-ATPase inhibitors were significantly smaller
(*P,0.05, **P,0.01) as compared to the RANKL-treated control
(Fig. 5C), consistent with previous reports implicating V-ATPases
in the regulation of osteoclast formation [29,40].
Figure 2. Prevention of wear particle-induced osteolysis in vivo by saliPhe and bafilomycin – mCT analysis. (A) Representative mCT 3D
reconstruction images of selected focal area on the middle suture of mice calvaria from sham, wear particle-induced osteolysis group (vehicle),
saliPhe treated group (low dose - 250 nM; or high dose - 500 nM), and bafilomycin treated group (low dose - 100 nM; or high dose - 250 nM).
Osseous property analysis from each group was measured from the selected focal area of the middle suture. (B and C) The amount of bone mass (%
BV/TV) and the amount of bone resorption volume expressed as a percentage of porosity of the whole calvaria (% Total Porosity) was measured. The
asterisks indicate significant differences between the inhibitors and vehicle control (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0034132.g002
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To further explore the underlying mechanisms for the inhibitory
effect of saliPhe and bafilomycin on osteoclast formation, we next
examined the effects of these V-ATPase inhibitors on classical
signaling pathways involved in osteoclastogenesis such as NF-kB,
ERK and NFATc1. As expected, western blot analysis revealed that
followingRANKLstimulation,IkBaaninhibitorysubunitofNF-kB
is phosphorylated and rapidly degraded (within minutes of
stimulation) (Fig. 6A, control). By comparison, IkBa degradation
and phosphorylation were notably perturbed in the presence of
either saliPhe or bafilomycin (Fig. 6A) implying a disruption in NF-
kB activation. Attenuation of NF-kB activation was further
confirmed by a luciferase reporter assay using a stable RAW264.7
(pseudo-osteoclastic) cell line carrying NF-kB luciferase reporter
construct. Activation of the NF-kB luciferase reporter gene was
demonstrated following RANKL stimulation and this activation was
dose-dependently suppressed by both saliPhe and bafilomycin
treatments (Fig. 6B; *P,0.05, **P,0.01). Additionally, RANKL-
induced ERK1/2 phosphorylation was also attenuated by saliPhe
and bafilomycintreatment (Fig. 6C). Onthe otherhand,saliPheand
bafilomycin had little effect on TRAF6 and NFATc1 expression
(Fig. 6D), suggesting that the inhibitory effect on osteoclast
formation by the V-ATPase inhibitors is primarily through the
suppression of NF-kB and ERK1/2 signaling pathways.
Discussion
Periprosthetic osteolysis and subsequent aseptic loosening
remains one of the most common complications limiting the
long-term durability of TJA and is the major instigator underlying
complex joint revision arthroplasty operations [1,4,41]. Extensive
efforts have been made to improve the implant designs,
biomaterials, and sterilization and surgical techniques. However,
these approaches are unlikely to eliminate particle generation from
bearing surfaces that stimulate a cascade of adverse biological
reactions causing osteolysis and loosening that leads to failure of
the total joint replacement [3,4,5,6]. With our increasing
understanding of the cellular and molecular events involved in
particle-induced osteolysis, it has become apparent that develop-
ment of novel strategies through pharmacological interventions is
a viable option for the extension of the life span of TJA. Here, we
demonstrate for the first time that the V-ATPase inhibitor
saliphenylhalamide can attenuate wear particle-induced osteolysis
in a mouse calvarial model. In vitro biochemical and morphological
assays revealed that the inhibition of osteolysis is partially
attributed to a disruption in osteoclast acidification and polariza-
tion, both are prerequisites for osteoclast bone resorption.
Interestingly, saliPhe also impaired osteoclast differentiation via
the inhibition of the NF-kB and ERK1/2 signaling pathways.
In vivo wear particle-induced mouse calvarial osteolysis was used
as the model to explore the potential protective effect(s) of V-
Figure 3. SaliPhe and bafilomycin protect against wear particle-induced osteolysis in vivo– histological and histomorphometric
analysis. (A) Histological H&E appearance of murine calvarial tissues along the middle suture. Both H&E and TRAP staining were taken for at least 3
sections for each group. The sham section shows few inflammatory and osteolytic changes. The vehicle group shows marked inflammatory reaction
and prominent osteolysis, whereas the inhibitor treated groups reveal a reduction in both inflammation and osteolysis. White arrowheads indicate
TRAP positive osteoclasts. (B–D) Histomorphometric analysis of bone volume against tissue volume (% BV/TV), erosion area (the percentage of
infiltration fibrotic area against total tissue area), and the number of TRAP positive multinucleated osteoclasts (.3 nuclei) on the bone surface was
measured (*P,0.05, **P,0.01 against vehicle control).
doi:10.1371/journal.pone.0034132.g003
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dimensional reconstruction of the calvarial bone architecture by
mCT, demonstrated that titanium (Ti) particles indeed induced
significant middle suture bone destruction as compared to the
controls. Remarkably, this particle-induced osteolysis was signif-
icantly reduced when mice were treated with saliPhe. Further-
more, histological assessments confirmed the Ti particle-induced
osteolysis adjacent to the pronounced inflammatory reactive tissue
with marked increase in TRAP-positive multinucleated cells.
Treatment with saliPhe or bafilomycin attenuated the inflamma-
tory reaction, bone destruction, and bone erosion area associated
with particle-induced osteolysis. Collectively, these data demon-
strate, for the first time, that saliPhe can be effectively used for the
treatment of wear particle-induced osteolysis.
The molecular mechanism of action of saliPhe and bafilomycin is
likely mediated by the inhibition of V-ATPase-mediated acidifica-
tion, the essential process necessary for bone resorption. This is in
line with in vitro analysis demonstrating inhibition of acridine orange
fluorescence quenching, a sign of elevated cellular pH and impaired
acidificationbysaliPheandbafilomycin,the classicalmodeofaction
of V-ATPase inhibitors. In addition to V-ATPase-mediated
acidification for bone resorption, osteoclasts must first undergo
membrane polarization to form an F-actin ring/sealing zone
surrounding the resorption area from the extracellular space. V-
ATPase has also been implicated in modulating cytoskeletal F-actin
assembly via association of the B and C subunits of the V1 domain
of the V-ATPase complex with F-actin filaments [25,42,43,44,45].
Additionally, deletion of the C1 subunit severely disrupted the
formation of the F-actin ring and this effect was proposed to be
independent of the V-ATPase activity though the underlying
mechanism which remains to be established [25]. Consistent with
this non-canonical role in modulating F-actin assembly, we
observed disruption of intact F-actin ring formation upon treatment
of mature osteoclasts with either saliPhe or bafilomycin. Interest-
ingly, the appearance of the F-actin rings disruption was
morphologically distinct from the control group, though the precise
reason of such discrepancy is presently unclear. Both saliPhe and
bafilomycin treated cells formed irregularly small and more
numerous F-actin rings. However, the limitation of our study on
disruption of F-actin ring by the V-ATPase inhibitors is the lack of
sufficient mechanistic data to demonstrate the indirect involvement
of C1 and B2 of the V1 domain.
An interesting yet unexpected observation of the current study is
the effect of V-ATPase inhibitors on RANKL-induced signaling
cascades including ERK, JNK, p38, and transcription factor NF-
kB [40]. V-ATPase has been shown to directly interact with
TRAF6 which is a crucial upstream regulator of NF-kB signaling
[46]. Our study has shown that both saliPhe and bafilomycin
inhibited the phosphorylation and degradation of IkBa protein
necessary for NF-kB nuclear shuttling and transcriptional activity
Figure 4. SaliPhe and bafilomycin inhibit osteoclastic bone resorption in vitro. (A) Pre-osteoclasts cultured on bone discs were incubated in
the presence or absence of saliPhe (10 nM, 20 nM, 40 nM, or 80 nM) or bafilomycin (0.625 nM or 1.25 nM) for 48 hrs for assessment of effect on bone
resorption. Bone resorption pits were examined by scanning electron microscopy (SEM). (B) The resorbed area on each bone disc was quantified as a
percentage of the total bone disc area. Data representative of 3 independent experiments performed in triplicates (mean 6 SEM; *P,0.05, **P,0.01
against control). (C) F-actin ring formation in activated osteoclasts. Osteoclasts cultured on bone discs and treated with saliPhe (80 nM) or
bafilomycin (1.25 nM) were stained for the formation of F-actin ring with Alexa-Fluor 647 phalloidin and imaged on NIKON confocal system with 406
oil emersion lens.
doi:10.1371/journal.pone.0034132.g004
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pathway which plays a role in osteoclast formation, function and
survival. NF-kB activation has also been directly linked to the
development of prosthetic osteolysis during inflammation. Wear
debris particles have been shown to activate NF-kB in various
macrophage cell systems and induce the production of TNFa and
IL-6 that modulates the inflammatory response as well as
osteoclast formation [12,18,47,48]. Thus, the potent inhibitory
effect of saliPhe and bafilomycin A1 on Ti-particle induced
osteolysis in vivo could possibly be a biphasic effect on inhibition of
bone destruction and suppression of inflammatory response.
However, further studies on the inflammatory process is required.
Conclusions
We have demonstrated the therapeutic potential of the novel
marine metabolite V-ATPase inhibitor, saliphenylhalamide on Ti
particle-induced osteolysis. The mechanisms are likely attributed
to the classical effect on V-ATPase-mediated bone resorption by
osteoclasts, as well as non-canonical impairment of osteoclast
activation and formation. Future studies are required to examine if
V-ATPase inhibitors may also have an unexplored role in
attenuating particle-induced inflammation.
Materials and Methods
Reagents
Saliphenylhalamide (saliPhe) was a kind gift from Prof. Jef K.
De Brabander at Department of Biochemistry, University of
Texas, Southwestern Medical Center (Dallas, USA). Bafilomycin
was purchased from Sigma. Commercial pure titanium (Ti)
particles, with average diameter of 4.50 mm, were purchased from
Johnson Matthey and prepared as previously described [49]. The
particles were sterilized by baking at 180uC for hrs, followed by
treatment with 70% ethanol for 48 hr to remove possible
endotoxin. The particles’ endotoxin level was measured
(,0.1EU/ml) using a commercial detection kit (Chromogenic
End-Point TAL with Diazo Coupling Kit, Xiamen Houshiji,
Fujian, PRC). GST-RANKL160–318 (rRANKL) recombinant
proteins were expressed and purified in our laboratory as
previously described [50]. Acridine orange was purchased from
Sigma. Antibodies used include mouse monoclonal anti-b-actin
(JLA20) (DSHB University of Iowa), rabbit polyclonal anti-IkBa
(Santa Cruz), mouse monoclonal anti-p-IkBa (Santa Cruz), rabbit
polyclonal anti-ERK1/2 (Promega), mouse monoclonal anti-p-
ERK1/2 (Santa Cruz), rabbit polyclonal anti-TRAF6 (Santa cruz)
and mouse monoclonal anti-NFATc1 (BD Pharmingen). All
antibodies were used at the concentrations recommended by the
supplier. Alexa Fluor 647-Phalloidin was from Molecular Probes
(Invitrogen). Luciferase substrate was from Promega.
Titanium particle-induced osteolysis mouse model
Wear particle-induced osteolysis model were generated as
previously reported [51]. In brief, titanium particles were washed
continuously in 100% ethanol for 48-hrs to remove adherent
endotoxins, followed by resuspension in sterile PBS solution at a
concentration of 300 mg/ml. A total of 30 8-week old C57BL/J6
mice divided into 6 groups of 5 mice were used. Thirty milligrams
of titanium particles were embedded under the periosteum around
the middle suture of the mice to induce bone destruction (5
groups). A group of mice was used as sham control. All procedures
are in accordance with the official guidelines for animal care of the
Figure 5. SaliPhe and bafilomycin impair osteoclast formation in vitro. (A) M-CSF-dependent BMMs were stimulated with 100 ng/ml RANKL
in the presence or absence of saliPhe (10 nM, 20 nM, 40 nM, or 80 nM) or bafilomycin (0.625 nM or 1.25 nM) for 5 days for the formation of
multinucleated osteoclasts. Cells were fixed and stained for TRAP activity. The number (B) and average size in areas (mm
2)( C) of TRAP positive
multinucleated osteoclasts (.3 nuclei) were quantified. Data representative of 3 independent experiments performed in triplicates (mean 6 SEM;
*P,0.05, **P,0.01 against control).
doi:10.1371/journal.pone.0034132.g005
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China; Animal Ethics Approval #201040). Two days post-
implantation of titanium particles, indicated V-ATPase inhibitors
or PBS were injected into the periosteum every other day for
14days before sacrifice and proceeded for further analysis. No
adverse affects or fatalities were noted.
Osteoclastogenesis and bone resorption
Adherent MCSF-dependent BMMs isolated from C57BL/J6
mice were seeded in a 96-well plate at density of 6610
3 cells per
well and stimulated with 100 ng/ml rRANKL and 10 ng/ml M-
CSF in the presence or absence of saliPhe (10 nM, 20 nM, 40 nM,
and 80 nM) or bafilomycin (0.625 nM and 1.25 nM) for 5 days for
the formation of multinucleated osteoclasts. After 5 days culture,
cells were fixed in 4% paraformaldehyde and stained for TRAP
activity. TRAP positive cells which contained 3 or more nuclei
were scored as mature osteoclasts, and cell spread area were
measured. BMMs derived preosteoclasts (3days osteoclastogenesis)
were seeded on bovine bone discs and stimulated with rRANKL
and M-CSF in the presence or absence saliPhe or bafilomycin as
described. After 48 hours culture bone discs were fixed in 4%
paraformaldehyde and stained for TRAP activity. The number of
Figure 6. SaliPhe and bafilomycin impair the NF-kB and ERK1/2 signalling pathway. (A) The effect of saliPhe and bafilomycin on RANKL-
induced IkBa phosphorylation and degradation. M-CSF-dependent BMMs pretreated with or without saliPhe (80 nM) or bafilomycin (1.25 nM) were
stimulated with 100 ng/ml RANKL for the indicated duration. Cells were lysed and analysed by western blot using anti-p-IkBa and anti-IkBa antibody.
Antibody against b-actin was used as loading control. (B) The effect of saliPhe and bafilomycin on NF-kB activation. RAW264.7 cells stably transfected
with the p-NF-kB-TA-Luc luciferase reporter gene were pretreated with saliPhe (80 nM) or bafilomycin (1.25 nM) prior to stimulation with RANKL
(100 ng/ml) for 8 hrs. Cell lysates were harvested and luciferase activity was measured. Relative luciferase response was plotted. Data representative
of 3 independent experiments performed in triplicates (mean 6 SEM; *P,0.05, **P,0.01 against control). (C) The effect of saliPhe and bafilomycin on
ERK1/2 signalling pathway. BMMs pretreated with or without saliPhe (80 nM) or bafilomycin (1.25 nM) were stimulated by RANKL for the indicated
duration. The expression of ERK1/2 and phosphorylated ERK1/2 were probed using corresponding antibodies. (D) The effect of saliPhe and
bafilomycin on TRAF6 and NFATc1 induction. M-CSF-dependent BMMs pretreated with or without saliPhe (80 nM) or bafilomycin A1 (1.25 nM) was
stimulated with 100 ng/ml RANKL for the indicated duration. Cells were lysed and analysed by western blot using anti-TRAF6 and anti-NFATc1
antibody. Antibody against b-actin was used as loading control.
doi:10.1371/journal.pone.0034132.g006
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quantified prior to assessment of resorptive activity. Resorption
pits were visualized by scanning electron microscopy. ImageJ
(NIH) software was used to quantify bone resorption parameters.
Intracellular acidification by acridine orange staining
Intracellular acidification was determined by acridine orange
(AO) fluorescence quenching method. BMM-derived osteoclasts
treated with saliPhe or bafilomycin for 24 hrs were serum-starved
for 2 hrs followed by incubation with 5 mg/ml AO (Sigma) for
30 mins at 37uC. Cells were washed and processed for fluorescent
microscopy analysis on a NIKON Eclipse TE2000-S fluorescence
microscope and associated software or fluorescence measured on
FLUOStar Optima spectrophotometer (BMG LabTech) at
excitation 492 nm and emission 535 nm. In addition, mature
osteoclasts were also incubated with 5 mg/ml AO (Sigma) for
30 mins at 37uC and baseline acidification was recorderd prior to
the addition of V-ATPase inhibitors and the effect on acridine
orange quenching was chased under fluorescent microscope for 5
and 10 mins to study the change of intracellular acidification after
V-ATPase inhibitors treatment.
F-actin ring immunofluorescence
For F-actin ring immunofluorescent staining, saliPhe or
bafilomycin treated osteoclasts cultured on bovine bone discs
were fixed with 4% paraformaldehyde for 15 min and permea-
bilized for 5 mins with 0.1% v/v Triton X-100. Cells were
incubated with Alexa-Fluor 647 phalloidin diluted in 0.2% w/v
BSA-PBS for 1 hr, washed extensively with 0.2% w/v BSA-PBS
and PBS, and finally mounted with ProLong Gold anti-fade
mounting medium (Invitrogen). Detection of fluorescence was
carried out on the NIKON A1Si spectral detector confocal system
equipped with 406(oil) lenses. Fluorescence images were collected
using the systems NIS-C Elements software and analysed using
ImageJ.
Western blot
Total cellular proteins were extracted from cultured BMM cells
using RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1%
Nonidet P-40, 0.1% SDS, 1% sodium deoxycholate) supplement-
ed with Protease Inhibitor Cocktail (Roche). Lysates were cleared
by centrifugation at 16,000 g for 10 mins at 4uC and supernatant
containing proteins were collected. For immunoblotting, extracted
proteins diluted in SDS-sampling buffer were resolved by SDS-
PAGE (10–15%) gels and then electroblotted onto nitrocellulose
membranes (Hybond ECL, Amersham Life Science). Following
transfer, membranes were blocked with 5% skim milk in TBS-
Tween (TBS; 0.05 M Tris, 0.15 M NaCl, pH 7.5 and 0.2%
Tween-20) for 1 hr and then probed with primary antibodies
diluted in 1% (w/v) skim milk powder in TBS-Tween for 2 hrs.
Membranes were washed and then incubated with HRP-
conjugated secondary antibodies and antibody reactivity was
detected by the Western Lightning Ultra Detection Kit (Perkin
Elmer) using the FujiFilm LAS-3000 Gel Documentation System
(FujiFilm) and its associated software.
NF-kB luciferase reporter gene assay
To examine NF-kB activation, RAW264.7 cells stably trans-
fected with a luciferase reporter gene p-NF-kB-TA-Luc [52], were
plated in 24-well plate at a density of 1610
5 cells per well and pre-
treated with saliPhe or bafilomycin A1 for 1 hr prior to rRANKL
stimulation (100 ng/ml) for a further 8 hrs. Cell lysates were
harvested and luciferase activity measured using the Promega
Luciferase Assay System according the manufacturer’s instructions
(Promega). RAW264.7 subclone C4 was kindly provided by Dr.
A.I. Cassady from the Centre for Molecular and Cellular Biology,
Department of Biochemistry, University of Queensland.
Micro-CT scanning
A high-resolution micro-CT (Skyscan 1072; Skyscan, Aartse-
laar, Belgium) was used to perform qualitative and quantitative
analyses of osteolysis in mouse calvaria. In order to reduce metal
artifact, the wear particles were removed before mCT scanning. A
thickness of 9.1 um for each slice was used for scanning the whole
calvaria. After reconstruction, a square region of interest (ROI)
around the midline suture was chosen for further qualitative and
quantitative analysis, with bone volume against tissue volume
(BV/TV) and percentage of total porosity of each sample
measured according to previous literatures [53]
Histological and histomorphometric analysis
After mCT analysis, the samples were decalcified in 10% EDTA
(pH 7.4) at 4uC for 2 weeks, followed by paraffin embedding. For
the middle suture osteolysis area analysis, non-osseous tissue area
adjacent and in continuity with the midline suture was taken as the
osteolysis area, and calculated with Image Pro-Plus 5.0 (Media
Cybernetics, USA). Five consecutive H&E stained sections were
calculated. In addition, TRAP staining was performed for
counting TRAP positive multinucleated osteoclasts in each
sample.
Semi-quantitative Reverse Transcription (RT)-PCR and
Real-time qPCR
Total cellular RNA was isolated from cultured cells using
RNeasy Mini Kit (QIAGEN) in accordance with the manufac-
turer’s protocol. For RT-PCR, single-stranded cDNA was reverse
transcribed from 2 mg total RNA using reverse transcriptase with
oligo-dT primer. All PCR was carried out using 1 ml of each
cDNA using the following cycling parameters 94uC, 40 secs; 60uC,
40 secs; and 72uC, 40 secs for 30 cycles with primers as:
Atp6v1b2: Forward: ACGCTGAAGCGCTGCGAGAG; Re-
verse: CCTTCCACTCGACCGGCACG; Atp6v1c1: Forward:
ACGCTCGCAGAAATGGTAGT; Reverse: TGCTTTCATC-
TCCTCCTCGT; 18S: Forward; ACCATAAACGATGCCG-
ACT; Reverse: TGTCAATCCTGTCCGTGTC. PCR samples
were analyzed by DNA agarose gel electrophoresis. For real-time
qPCR analysis, corresponding PCR primers were used and
performed on a 96-well plate ABI Prism 7000 Sequence Detection
system (Applied Biosystems, USA) using SYBR Green PCR
Master Mix (QIAGEN). Cycling conditions was as follows 95uC,
15 secs; 60uC, 20 secs; and and 72uC, 1 min for 40 cycles. The
comparative 2
2DDCT method was used to calculate the relative
expression of each target gene and the expression level of all genes
were normalized to the expression level of the house keeping gene.
Bioluminescence Resonance Energy Transfer (BRET)
Assay
BRET expression constructs were constructed as previously
described [54]. Briefly, mouse sequence for V-ATPase V0 domain
subunits a3, c, c0, e and accessory subunit Ac45 were fused to the
mammalian expression vector pcDNA3.1 containing the Renilla
luciferase (Rluc) donor fluorophore or EYFP-fused acceptor
fluorophore. HEK293 cells were transiently co-transfected with
both donor and acceptor constructs using Lipofectamine2000
transfection reagent in 6-well plates. Forty-eight hours post-
transfection cells were harvest by trypsinization and ,3610
4 cells
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of V-ATPase inhibitors. Coelenterazine-h substrate (Promega) was
added to a final concentration of 5 mM and readings immediately
collected within the 475 nm (Rluc) and 530 nm (EYFP) windows
after addition of the substrate using the PolarStar Optima
Spectrofluorometer (BMG Labtechnologies) and its associated
software. BRET ratios for the co-expression of Rluc and EYFP
constructs were normalized against the control group. Data
presented is representative of three independent experiments.
Statistics & Data Presentation
Results were statistically analyzed using a two-tailed Students T-
test using Microsoft Excel (Microsoft Corp.) and data shown
represent one of at least three independent experiments.
Supporting Information
Figure S1 SaliPhe and bafilomycin do not alter V0
subunits interaction and V1 subunits B2 and C1
expression. (A) The interaction of V0 domain subunits in the
absence or presence of V-ATPase inhibitors by BRET assay. (B)
Gene expression of V-ATPase subunit B2 and C1 in osteoclasts
after saliPhe or bafilomycin treatment by RT-PCR. (C) qPCR for
quantification of the expression of V-ATPase subunit B2 and C1
after V-ATPase inhibitors treatment.
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